In the recent times, Expansion Therapeutics has been on the forefront raising finances in support for initiating the fight against genetic disorders. One of the major defection include myotonic dystrophy type I. It is also known as DM1. It is one of the causes of muscular dystrophy among adults. In response to this and many others, the company has availed $55.3 million among other funds in the fight against it. It is believed that the symptoms are expressed when the ribonucleic acids reach a toxic level in the body. A group of volunteer individuals and companies accomplishes the financing. They include Novartis Venture Fund, Sanofi Ventures, 5AM Ventures, RA Capital Management, Kleiner Perkins, and Alexandria Venture Investments.

 

In details, RNAs are DNA molecules that are transferred, and they are then converted into proteins. In case the production of these RNAs reaches lethal levels within the cells, DM1 condition happens. This condition makes all the systems in the body to be defective. The likes of hormonal, respiratory, cardiac, gastrointestinal, and central nervous systems become weak in their functions. The worst result is that this condition is transferrable from one generation to another. It becomes a genetic issue. In the current medical world, the treatment for this condition is yet to be found.

 

Expansion Therapeutics majors in the creation of medicines that can cure all illnesses related to RNA. Most of its concerns lie in expansion repeat disorders. These disorders are inherited from one generation to another and are seen to respond slowly to medical interventions available. The defective genes cause them. The company takes time to research the Matthew D. Disney laboratory. A wonderful managing partner at 5AM Ventures, Scott Rocklage gave a press release that addressed the matter. Scott went to University of California in Berkeley where he received a degree in Bachelor of Science in Chemistry. He later went to Massachusetts Institute of technology and got a Ph.D. in Chemistry. During his times at MIT, Scott Rocklage was deep in research at Richard R. Schrock laboratory. He received the Nobel Peace Prize in 2005 in Chemistry. Scott Rocklage joined as a venture partner at 5AM Ventures in 2003 and later on became a managing partner in 2004. Lean more: http://people.equilar.com/bio/scott-rocklage-cidara-therapeutics-/salary/913398#.WWaMA9PytTY

Written by


Leave a Reply

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>